Avenge Bio
Por um escritor misterioso
Descrição
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Closes $45 Million Series A Financing
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
avengebio (@AvengeBio) / X
Avenge Bio secures FDA designation for mesothelioma therapy
Biotech, Pharmaceutical and Clinical Research News
Avenge Bio to Begin Clinical trials of Immunotherapy Technology, Department of Bioengineering
BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial
Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Michael Heffernan
Douglas Carlson on LinkedIn: Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial…
David Schull on LinkedIn: Clinically translatable cytokine delivery platform for eradication of…
de
por adulto (o preço varia de acordo com o tamanho do grupo)
